CARMA FUND
CARMA FUND I is an early-stage investment fund for advancing Life Science and Healthcare technologies. The fund started off with a First Closing in June 2022 and has €56M under management. It is based in Munich and Frankfurt am Main. Starting to develop new products and services for the patients’ well-being and medical advancements comes with its unique challenges and opportunities. Biotech/healthcare is a specialist business and as such innovators have often struggled to rope in reliant streams of outside capital necessary for quick and effi cient development towards a market entry. The Fund was initiated by the two technology transfer companies Innovectis (Frankfurt) and Ascenion (Munich).
Ansprechpartner
Dr. Martin Raditsch
General Partner
Capital under management
CARMA has €56M under management.
Investment requirements and financing offer
CARMA FUND I is uniquely suited for young Eurpean companies and projects from the Life Science and medical space due to an extra-long term, flexible investment modes and its relationships with leading technology transfer offi ces and industry partners.
CARMA invests in pre-seed, seed, and series A.
Industry focus
CARMA FUND is investing in opportunities from the European Life Science and Healthcare sector.
THERAPEUTICS
MEDTECH
DIAGNOSTICS
DIGITAL HEALTH
Portfolio and exits
Acorai, Aignostics, Allogenetics, Akribion, Ceregate, Dimericon Therapeutics, Epignostix, Genome Biologics, Incontalert, Kupando, O11 Medical, Salvina, Symphera, Tecregen, Thryve, Elkedonia
Memberships in networks/associations
ASTP: This association is Europe’s association of knowledge transfer professionals with two decades of experience in educating, connecting and advocating for the profession.
bioRN, the science and industry innovation cluster in the Rhine-Neckar region around Heidelberg
Date of foundation/ Number of employees
June 2022/4
Kontaktdaten
Address: Herzogstrasse 64, München 80803
Telephone: +49 15153946465
E-Mail: martin.raditsch@carma-fund.com
Social Media: www.linkedin.com/in/martin-raditsch
Web Address: www.carma-fund.com
- Summit of the Brave statt Valley of Death
- Gegen die Löcher auf der Straße
- AI in Drug Development: Where Value is Emerging
- „Die Life Sciences-Branche verfügt nach wie vor über enormes Potenzial“
- Pre-Seed für Onyx Biotech
- DBT 2026: Morgens um 8 in Deutschland
- Viromed Medical AG
- MIG Capital beteiligt sich an 35-Mio.-EUR-Finanzierung von TIBEAY Biosciences
- Wagnis für Wagniskapital mit 14leafs: 50 Milo. EUR aus Würzburg
- Gilead Sciences übernimmt ADC-Unicorn Tubulis für bis zu 5 Mrd. USD
- Vom Start-up-Pitch bis zur Börsenoption: Biotech & Finance Day auf der analytica 2026
- Alles neu beim ECBF
- iDEL Therapeutics sichert sich 9 Mio. EUR Seed-Finanzierung
- „Mut ist ein messbares Execution-Risiko, das wir aktiv managen“
- „Wir brauchen nicht nur Einhörner, sondern den ganzen Zoo“
- „Wir sind eine Investitionsarchitektur für langfristige Wertschöpfung“
- ‘‘We build a leading global platform for precision healthcare‘‘
- „Gesund durch Pharma, Ernährung und Digitale Therapien“
- „Wir wollen den Industrien kein ‚Weiter-so‘ ermöglichen“
- „Die finanziellen Mittel sind im Markt per se vorhanden“


